The insurer had until the end of March to correct faulty data submissions or be hit with severe sanctions from the CMS. But regulators agreed to give Elevance more time to comply.
Elevance sidesteps Medicare Advantage sanctions for now Read More »
As Novo Nordisk cuts 400 jobs at the troubled site, Scholar Rock has seen enough progress that it included the facility in a resubmission for FDA approval.
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment Read More »
The FDA approved Eli Lilly’s orforglipron—to be known as Foundayo—on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry Read More »
Hospitals in 16 states have sued the department, arguing a 2023 final rule underpays hospitals that treat a disproportionate number of low-income patients.
Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat heart attack patients who don’t have cardiogenic shock.
J&J’s Impella heart pump shows no patient benefit in 2 trials Read More »
Senators praised a recent CMS proposal aimed at reducing payments in MA, but urged the agency to work with Congress and go further.
Bipartisan lawmakers urge CMS to crack down on Medicare Advantage overpayments Read More »
Of the 11 companies participating in the spring cohorts of the Drive program run by MassBio and SCbio, eight have locations in Massachusetts. One cohort focuses on biotech and the other on biomarkers and diagnostics.
11 Startups Selected for National Life Sciences Accelerator Program Read More »
La revolución digital ha impactado prácticamente todos los sectores, pero el universo de las apuestas online se encuentra a la vanguardia gracias a la irrupción de la tecnología blockchain. En poco tiempo, conceptos que antes resultaban ajenos para muchos, como la descent …
The FDA advised IO Biotech last year to hold off on filing an approval application for its cancer vaccine Cylembio, pointing to a failed Phase 3 study in frontline advanced melanoma. The biotech has now gone under.
The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile. The pharma refused.
